Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis

September 23, 2026 updated by: Sara Taher Mohamed Amin, Assiut University

The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are Lung Ultrasound and a blood marker called Growth Differentiation Factor-15 (GDF-15).

The main question it aims to answer is:

Does the combination of these 2 modalities have the diagnostic accuracy similar to the gold standard test which is High Resolution Computed Tomography (HRCT) of the Lungs? Does this combination have the potential to become a validated screening tool?

Participants will be in 2 groups: the RA group and the SSc group, each will have the diagnostic combination and a reference HRCT for comparison of results.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Interstitial lung disease (ILD) represents one of the most severe extra-articular and systemic manifestations of Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc). ILD significantly increases morbidity and remains a leading cause of mortality in both disease entities.

Accumulating evidence demonstrates a high prevalence of subclinical interstitial lung disease, occurring in up to 33% of patients with rheumatoid arthritis and 50% of patients with systemic sclerosis. Therefore, Early detection during this subclinical window is paramount to initiate timely immunomodulatory or antifibrotic therapies before irreversible fibrotic replacement occurs.

Although high-resolution computed tomography (HRCT) of the chest remains the gold standard for diagnosing interstitial lung disease, its high cost and associated radiation exposure restrict its utility as a routine screening tool for all patients, particularly in resource-limited settings. Consequently, there is a clinical demand for a validated, non-invasive, radiation-free, and cost-effective triage tool to screen populations at risk and identify those who genuinely require diagnostic HRCT evaluation.

Growth Differentiation Factor-15 (GDF-15), a stress-responsive cytokine belonging to the Transforming Growth Factor-beta (TGF-β) superfamily, has emerged as a novel systemic biomarker reflective of cellular stress, inflammation, and fibrogenesis . GDF-15 is significantly elevated in active systemic autoimmune conditions such as Behcet disease, Inflammatory bowel disease and Sjogren's disease . Importantly, GDF-15 is overexpressed in pulmonary epithelial cells during active fibrogenesis and serves as a key circulating biomarker in idiopathic pulmonary fibrosis as well as connective tissue disease-associated ILD and pulmonary hypertension.

As a cellular stress cytokine, serum GDF-15 reflects the distinct pathogenetic mechanisms driving ILD in each condition:

RA-ILD: Mucosal citrullination and anti-CCP immune complex deposition 2022induce alveolar epithelial injury and inflammatory cytokine release. Here, elevated GDF-15 primarily reflects acute epithelial stress and immune-mediated inflammatory intensity.

SSc-ILD: Microvascular damage and endothelial apoptosis trigger TGF-β signaling and myofibroblast expansion. Here, GDF-15 acts downstream of TGF-β, reflecting chronic endothelial ischemia and fibrogenesis.

Concurrently, point-of-care Lung Ultrasound (LUS) has revolutionized bedside assessment in rheumatology. LUS detects interstitial pulmonary changes-specifically B-lines and pleural line irregularities-with exceptional sensitivity. Recent evidence highlights that LUS achieves remarkable diagnostic accuracy compared to HRCT in both RA-ILD and SSc-ILD.

While GDF-15 reflects early molecular and cellular fibrotic activity and LUS identifies early structural lung affection, whether combining these two non-invasive modalities yields superior diagnostic accuracy for subclinical ILD screening compared to either modality alone remains unexplored. Combining a molecular circulating marker with a physical point-of-care imaging tool could establish a robust triage model for outpatient rheumatology clinics. Therefore, this is a diagnostic accuracy study to determine the outcomes of this combination.

Study Type

Observational

Enrollment (Estimated)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All adult patients diagnosed as RA "according to 2010 ACR/EULAR classification criteria" or SSc "according to 2013 ACR/EULAR classification criteria", either known to be complicated with ILD or not, are recruited from inpatient and outpatient clinic of Rheumatology and Rehabilitation department of Assiut University hospital

Description

Inclusion Criteria:

1- Adult patients (≥18 years) with confirmed diagnosis of RA or SSc.

Exclusion Criteria:

  1. Active respiratory tract infection or acute exacerbation of pulmonary disease.
  2. Other causes of pulmonary fibrosis such as history of heavy smoking (>15 pack-years) or significant environmental/occupational exposure known to induce pulmonary fibrosis.
  3. Pre-existing primary chronic lung diseases (e.g., COPD, bronchial asthma, active tuberculosis, severe bronchiectasis).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Rheumatoid arthritis patients

Either known to have ILD or not, Asymptomatic patients

Lung Ultrasound, 14 point protocol

Serum sample will be collected and ELISA test will be conducted

High resolution CT of the lungs

Systemic Sclerosis patients

Either known to have ILD or not, Asymptomatic patients

Lung Ultrasound, 14 point protocol

Serum sample will be collected and ELISA test will be conducted

High resolution CT of the lungs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the overall diagnostic accuracy (Sensitivity, Specificity, positive and negative predictive values) of combined GDF-15 + LUS compared to HRCT in screening for subclinical ILD in RA and SSc patients.
Time Frame: Baseline

All patients will undergo combined GDF-15 + LUS to determine their diagnostic accuracy

Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare baseline serum GDF-15 levels between RA-ILD and SSc-ILD cohorts to assess whether differing underlying pathogenetic mechanisms influence circulating GDF-15 concentrations and its diagnostic cut-off values.
Time Frame: Baseline

Cut-off values of GDF-15 will be determined for each group

Baseline
Evaluate the correlation between serum GDF-15 levels and the structural extent/severity of ILD on HRCT.
Time Frame: Baseline

Level of GDF-15 will be correlated with CT findings

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Essam Ahmed Abda, Professor, Professor of Rheumatology, Rehabilitation and Physical medicine
  • Study Director: Mohammed Raouf Abd El-razik, Assistant Professor, Assistant professor of Rheumatology, Rehabilitation and physical medicine
  • Study Director: Amira Mostafa El-Sonbaty, Lecturer, Lecturer of Rheumatology, Rehabilitation and Physical medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 15, 2026

Primary Completion (Estimated)

October 30, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

September 19, 2026

First Submitted That Met QC Criteria

September 19, 2026

First Posted (Actual)

September 24, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 23, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.